David E Kandzari

Summary

Affiliation: Piedmont Hospital
Country: USA

Publications

  1. doi request reprint Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Eur Heart J 36:219-27. 2015
  2. doi request reprint Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 6:504-12. 2013
  3. doi request reprint Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes
    David E Kandzari
    Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309, USA
    J Interv Cardiol 26:131-6. 2013
  4. doi request reprint Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Clin Cardiol 35:528-35. 2012
  5. doi request reprint Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coro
    David E Kandzari
    Department of Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:543-50. 2011
  6. pmc Revascularization for unprotected left main coronary artery disease: an evolution in clinical decision making
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Curr Cardiol Rep 13:424-31. 2011
  7. doi request reprint Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
    David E Kandzari
    Department of Interventional Cardiology, Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:1119-28. 2011
  8. doi request reprint Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes
    Dimitri Karmpaliotis
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Catheter Cardiovasc Interv 82:1-8. 2013

Detail Information

Publications8

  1. doi request reprint Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Eur Heart J 36:219-27. 2015
    ..Prior RDN studies have demonstrated significant and durable reductions in blood pressure. This analysis investigated factors that may help explain these disparate results...
  2. doi request reprint Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents
    David E Kandzari
    Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 6:504-12. 2013
    ..Santa Rosa, California) with first-generation drug-eluting stents (DES) and bare-metal stents (BMS)...
  3. doi request reprint Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes
    David E Kandzari
    Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, GA 30309, USA
    J Interv Cardiol 26:131-6. 2013
    ..To evaluate clinical and angiographic outcomes using a 1.20 mm diameter angioplasty catheter as part of a predilation strategy for coronary lesion treatment...
  4. doi request reprint Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA, USA
    Clin Cardiol 35:528-35. 2012
    ..This manuscript describes the design and methodology of a regulatory trial of selective renal denervation for the treatment of hypertension among patients who have failed pharmacologic therapy...
  5. doi request reprint Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coro
    David E Kandzari
    Department of Interventional Cardiology and Interventional Cardiology Research, Piedmont Heart Institute, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:543-50. 2011
    ..This study sought to compare late safety and efficacy outcomes following percutaneous coronary revascularization with zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES)...
  6. pmc Revascularization for unprotected left main coronary artery disease: an evolution in clinical decision making
    David E Kandzari
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Curr Cardiol Rep 13:424-31. 2011
    ....
  7. doi request reprint Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents
    David E Kandzari
    Department of Interventional Cardiology, Piedmont Heart Institute, Suite 300, 275 Collier Road, Atlanta, Georgia 30309, USA
    JACC Cardiovasc Interv 4:1119-28. 2011
    ..We sought to evaluate differences in late safety outcomes relative to dual antiplatelet therapy (DAPT) duration in patients treated with zotarolimus-eluting stents (ZES)...
  8. doi request reprint Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical, and cost-utilization outcomes
    Dimitri Karmpaliotis
    Piedmont Heart Institute, Atlanta, GA 30309, USA
    Catheter Cardiovasc Interv 82:1-8. 2013
    ..Development of a specialized chronic total coronary occlusion (CTO) revascularization program attentive to procedural guidelines, quality oversight, and cost/resource utilization has not been described...